Reusable Core Biopsy Instrument Market Global Report 2026

The reusable core biopsy instrument market size has grown strongly in recent years. It will grow from $1.03 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to rising incidence of cancer and chronic illnesses, increasing need for precise diagnostic procedures, wider adoption of image-guided biopsy methods, continued development of healthcare infrastructure, and growing preference for cost-efficient reusable medical instruments.

The reusable core biopsy instrument market size is expected to see strong growth in the next few years. It will grow to $1.62 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for advanced tissue sampling procedures, growing emphasis on sustainable reusable healthcare devices, rising adoption of precision biopsy workflows, expanding diagnostic screening initiatives, increasing demand for durable and high-performance biopsy instruments. Major trends in the forecast period include growing adoption of reusable precision biopsy instruments, increasing demand for cost-effective tissue sampling solutions, rising emphasis on enhanced sterilization and extended device longevity, increasing preference for consistent diagnostic sample quality, expanding adoption of minimally invasive biopsy procedures.

The rising incidence of cancer and chronic diseases is expected to propel the growth of the reusable core biopsy instrument market going forward. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can spread throughout the body, while chronic diseases are long-term health conditions that develop gradually and require continuous management. Cancer and chronic diseases are increasing primarily due to unhealthy lifestyles, including poor diet, physical inactivity, smoking, and alcohol consumption, which progressively damage the body over time. Reusable core biopsy instruments support the diagnosis of cancer and chronic diseases by enabling precise tissue sampling, allowing healthcare professionals to accurately determine the type and stage of a disease at an early stage and guide appropriate treatment decisions. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. Therefore, the rising incidence of cancer and chronic diseases is driving the growth of the reusable core biopsy instrument market.

The increasing adoption of minimally invasive procedures is expected to propel the growth of the reusable core biopsy instrument market going forward. Minimally invasive procedures are medical treatments that involve small incisions or natural body openings and specialized instruments to reduce tissue damage, pain, and recovery time compared to conventional open surgery. The use of minimally invasive procedures is increasing as patients seek faster recovery, reduced pain, and shorter hospital stays, while healthcare systems benefit from lower overall treatment costs and greater operational efficiency. Reusable core biopsy instruments support minimally invasive procedures by allowing healthcare professionals to obtain accurate tissue samples through small incisions with high precision, reducing the need for open surgical techniques and helping minimize patient trauma and recovery time. For instance, in June 2024, according to the American Society of Plastic Surgeons, a US-based organization, minimally invasive procedures increased by 7% in 2023 compared to the previous year. Therefore, the increasing adoption of minimally invasive procedures is driving the growth of the reusable core biopsy instrument market.

Key companies operating in the reusable core biopsy instrument market are increasingly prioritizing integrated biopsy systems with adjustable actuation and precision tissue-sampling capabilities to improve biopsy accuracy, preserve tissue integrity, and support reliable pathological diagnosis. These systems combine reusable actuator instruments with biopsy needles designed to obtain full-length, unbroken tissue cores, enabling clinicians to collect representative samples while controlling sampling depth and reducing the risk of under- or overshooting the target. For example, in January 2025, Triopsy Medical, Inc., a US-based medical device company, received FDA 510(k) clearance for its Triopsy Integrated Biopsy System, comprising the Triopsy Actuator and Triopsy Biopsy Needle. The FDA classified the device as a gastroenterology-urology biopsy instrument, and the cleared system uses a reusable actuator with a disposable biopsy needle for prostate tissue sampling. The needle incorporates patented ridges designed to hold and protect the tissue sample, while the actuator provides variable sample lengths for different prostate biopsy locations. By combining a reusable actuation platform with precision tissue-sampling technology, the Triopsy system supports more controlled prostate biopsies and aims to improve the quality and integrity of tissue cores used for pathological assessment.

Major companies operating in the reusable core biopsy instrument market are Becton Dickinson and Company (BD), Cook Group Inc. / Cook Medical, Argon Medical Devices Inc., STERYLAB S.r.l., MDL S.r.l., BIP Medical S.r.l. / BIP GmbH, UROMED Kurt Drews GmbH, GEOTEK MEDICAL, Biomedical Srl, Iscon Surgicals Ltd., Chamfond Biotech Co. Ltd., Vigeo S.r.l., Histo S.r.l., SteryMed S.r.l., Advin Health Care, Meditech Devices Pvt. Ltd., Matek Medical, Adria Medical.

North America was the dominant region in the reusable core biopsy instrument market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the reusable core biopsy instrument market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the reusable core biopsy instrument market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.